<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">WARM, MATHIAS</style></author><author><style face="normal" font="default" size="100%">KATES, RONALD</style></author><author><style face="normal" font="default" size="100%">THOMAS, ANKE</style></author><author><style face="normal" font="default" size="100%">FISCHER, THOMAS</style></author><author><style face="normal" font="default" size="100%">HARBECK, NADIA</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Side-effects of Pre-operative Epirubicin-Paclitaxel Therapy in Primary Breast Cancer Associated with Tumor Biology</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2675-2680</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><issue><style face="normal" font="default" size="100%">7</style></issue><abstract><style  face="normal" font="default" size="100%">Background: The objective of this analysis is to identify relationships between side-effects, tumor biological factors and response to pre-operative epirubicin and paclitaxel therapy in primary breast cancer. Patients and Methods: The study was completed for 38 primary breast cancer patients (M0) who received pre-operative epirubicin and paclitaxel chemotherapy. Anemia was controlled by epoetin alfa and did not cause deviations from the planned chemotherapy schedule. Results: There were no severe adverse events, cardiotoxicity or neutropenia. Patients with negative estrogen or progesterone receptors, or high KI-67 suffered more alopecia, while HER2 overexpressing patients had less severe nausea. Conclusion: This pre-operative chemotherapy regimen was well tolerated on the whole; side-effect profiles were correlated with tumor biological factors and also with response.</style></abstract></record></records></xml>